Investor Relations

Press Releases

Date Title and Summary View
Nov 18, 2014
PRINCETON, N.J., Nov. 18, 2014 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX) today announced that John Hubbard, Ph.D., FCP has been appointed to the Company's Board of Directors, effective November 18, 2014. Dr. Hubbard will serve on Agile's Nominating and Corporate Governance
Nov 13, 2014

Company Continues to Progress Clinical Trial Site Activation and Subject Enrollment

Oct 01, 2014
PRINCETON, N.J., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX) announced today that James P. Tursi, M.D. has been appointed to the Company's Board of Directors effective October 1, 2014. Dr. Tursi will serve on the Compensation Committee.
Sep 29, 2014
PRINCETON, N.J., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that the first patients have been dosed in its
Sep 22, 2014
PRINCETON, N.J., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari, President and Chief Executive
Sep 16, 2014
Twirla (AG200-15) is a Novel Low-Dose Combined Hormonal Contraceptive Patch Designed Using the Company's Proprietary Transdermal Skinfusion ® Technology Confirmatory SECURE Study To Build Upon Data From Previous Phase 3 Studies in Support of the Company's New Drug Application to the U.S.
Sep 02, 2014
PRINCETON, N.J. , Sept. 2, 2014 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Mr.
Aug 14, 2014

Company on Track With Initiation of Confirmatory Phase 3 Clinical Trial of Twirla(TM) in Third Quarter of 2014

Jul 17, 2014

Intellectual Property Portfolio Broadened for Its Proprietary Transdermal Delivery System

Jun 30, 2014
PRINCETON, N.J. , June 30, 2014 /PRNewswire/ -- Agile Therapeutics, Inc. , (NASDAQ: AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced it has been added to the Russell Microcap Index.